- Home
- ARVN
ARVN
Arvinas Inc.
as 01-21-2025 4:00pm EST
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 1.4B | IPO Year: | 2018 |
| Target Price: | $63.00 | AVG Volume (30 days): | 860.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.08 - $53.08 | Next Earning Date: | 02-25-2025 |
| Revenue: | $161,100,000 | Revenue Growth: | 1.07% |
| Revenue Growth (this year): | 239.85% | Revenue Growth (next year): | -21.83% |
Latest Arvinas Inc. News
ARVN Breaking Stock News: Dive into ARVN Ticker-Specific Updates for Smart Investing
Motley Fool
a day ago
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025
MT Newswires
12 days ago
Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure
GlobeNewswire
12 days ago
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
Clinical Trials Arena
a month ago
Arvinas and Pfizer’s combo therapy shows promise in breast cancer trial
Benzinga
a month ago
Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients
MT Newswires
a month ago
Arvinas, Pfizer Present 'Encouraging' Preliminary Data for Prospective Breast Cancer Treatment
GlobeNewswire
a month ago
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
Insider Monkey
2 months ago
Why Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
Compare ARVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARVN Arvinas Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.